Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib

"Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.~Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone."

Trial Locations (11)

15240

Pittsburgh VA Medical Center, Pittsburgh

30033

Atlanta VA Medical Center, Atlanta

33612

Tampa VA Medical Center, Tampa

64128

Kansas City VA Medical Center, Kansas City

72205

Little Rock VA Medical Center, Little Rock

77030

Michael E. DeBakey VA Medical Center, Houston

80220

Eastern Colorado Health Care System, Denver

90073

West Los Angeles VA Medical Center, Los Angeles

94121

San Francisco VA Medical Center, San Francisco

06516

West Haven VA Medical Center, West Haven

02130

VA Boston Healthcare System, Jamaica Plain

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Boston VA Research Institute, Inc.

OTHER